Clusterin inhibition to enhance tumor chemosensitivity in systemic tumors

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 4, 2013, Pages 1101-

  Kapoor, Shailendra ^a  

^a Private Practise   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; CLUSTERIN; CUSTIRSEN; PACLITAXEL; PROTEIN KINASE B; SMALL INTERFERING RNA; SORAFENIB; TAMOXIFEN; ANTINEOPLASTIC AGENT;

BLADDER CARCINOMA; CANCER PROGNOSIS; CHEMOSENSITIVITY; DOWN REGULATION; DRUG EFFICACY; HUMAN; INHIBITION KINETICS; KIDNEY CARCINOMA; LETTER; MALIGNANT NEOPLASTIC DISEASE; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SYSTEMIC DISEASE; TREATMENT OUTCOME; GENETICS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; NOTE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLUSTERIN; HUMANS; LUNG NEOPLASMS;

EID: 84878890891     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2072-6     Document Type: Letter

References (6)

1. Cheng CY, Cherng SH, Wu WJ et al (2012) Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells. Cancer Chemother Pharmacol 69:145-154
2. Kususda Y, Miyake H, Gleave ME, Fujisawa M (2012) Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model. Br J Cancer 106:1945-1952
3. Yamanaka K, Gleave M, Muramaki M, Hara I, Miyake H (2005) Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model. Oncol Rep 13:885-890
4. Gleave M, Miyake H (2005) Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol 23:38-46 (Pubitemid 40430679)
5. Cappelletti V, Gariboldi M, De Cecco L et al (2008) Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. Endocr Relat Cancer 15:439-449 (Pubitemid 351880833)
6. Hassan MK, Watari H, Han Y et al (2011) Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel. J Exp Clin Cancer Res 30:113